Yichao Wan

Dr. Yichao Wan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YWYichao Wan
Yichao Wan
YLYuanhua Li
Yuanhua Li
CYChunxing Yan
Chunxing Yan
MYMi Yan
Mi Yan
ZTZilong Tang
Zilong Tang

1 December 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YWYichao Wan
Yichao Wan
GFGuoqing Fang
Guoqing Fang
HCHongjuan Chen
Hongjuan Chen
XDXu Deng
Xu Deng
ZTZilong Tang
Zilong Tang

1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YWYichao Wan
Yichao Wan
JLJiabing Long
Jiabing Long
HGHan Gao
Han Gao
ZTZilong Tang
Zilong Tang

1 July 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GFGuoqing Fang
Guoqing Fang
HCHongjuan Chen
Hongjuan Chen
ZCZhiyun Cheng
Zhiyun Cheng
ZTZilong Tang
Zilong Tang
YWYichao Wan
Yichao Wan

9 April 2020 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
YWYichao Wan
Yichao Wan
CYChunxing Yan
Chunxing Yan
HGHan Gao
Han Gao
TLTingting Liu
Tingting Liu
Proteolysis-targeting chimera (PROTAC) is a new technology to selectively degrade target proteins via ubiquitin-proteasome system. PROTAC molecules (PROTACs) are a class of heterobifunctional molecules, which contain a ligand targeting the protein of interest, a ligand recruiting an E3 ligase and a linker connecting these two ligands. They provide several advantages over traditional inhibitors in potency, selectivity and drug resistance. Thus, many promising PROTACs have been developed in the recent two decades, especially small-molecule PROTACs. In this review, we briefly introduce the mechanism of PROTACs and focus on the progress of small-molecule PROTACs based on different E3 ligases. In addition, we also introduce the opportunities and challenges of small-molecule PROTACs for cancer therapy.

1 March 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SZSitao Zhang
Sitao Zhang
YCYanzhao Chen
Yanzhao Chen
CTChengsen Tian
Chengsen Tian
YHYujing He
Yujing He
ZTZeru Tian
Zeru Tian
TLTingting Liu
Tingting Liu
Background: Currently, cancer continues being a dramatically increasing and serious threat to public health. Although many anti-tumor agents have been developed in recent years, the survival rate of patients is not satisfactory. The poor prognosis of cancer patients is closely related to the occurrence of drug resistance. Therefore, it is urgent to develop new strategies for cancer treatment. Multi-target therapies aim to have additive or synergistic effects and reduce the potential for the development of resistance by integrating different pharmacophores into a single drug molecule. Given the fact that majority of diseases are multifactorial in nature, multi-target therapies are being exploited with increasing intensity, which has brought improved outcomes in disease models and obtained several compounds that have entered clinical trials. Thus, it is potential to utilize this strategy for the treatment of BRD4 related cancers. This review focuses on the recent research advances of dual-target inhibitors based on BRD4 in the aspect of anti-tumor. Methods: We have searched the recent literatures about BRD4 inhibitors from the online resources and databases, such as pubmed, elsevier and google scholar. Results: In the recent years, many efforts have been taken to develop dual-target inhibitors based on BRD4 as anti-cancer agents, such as HDAC/BRD4 dual inhibitors, PLK1/BRD4 dual inhibitors and PI3K/BRD4 dual inhibitors and so on. Most compounds display good anti-tumor activities. Conclusion: Developing new anti-cancer agents with new scaffolds and high efficiency is a big challenge for researchers. Dual-target inhibitors based on BRD4 are a class of important bioactive compounds. Making structural modifications on the active dual-target inhibitors according to the corresponding structure-activity relationships is of benefit to obtain more potent anti-cancer leads or clinical drugs. This review will be useful for further development of new dual-target inhibitors based on BRD4 as anti-cancer agents.